Note 5.

Revenues and Trade Receivables, Net

The Company’s revenue was comprised of the following:

	Year Ended December 31,
	2020		2019
Manufacture and supply revenue	$	24,881	$	38,739
License and royalty revenue		14,055		6,959
Co-development and research fees		1,264		4,042
Proprietary product sales, net		5,649		2,869
Revenues	$	45,849	$	52,609

Disaggregation of Revenue

The following table provides disaggregated net revenue by geographic area:

	Year Ended December 31,
	2020		2019
United States	$	40,956	$	48,293
Ex-United States		4,893		4,316
Revenues	$	45,849	$	52,609

Ex-United States revenues are derived primarily from Indivior for product manufactured for markets outside of the United States.

Accounts receivable, net consist of the following:

	December 31,
	2020			2019
Accounts receivable	$	4,330		$	9,094
Contract and other receivables		3,081			4,363
Less: allowance for bad debt		(40	)		(124	)
Less: sales-related allowances		(416	)		(203	)
Trade and other receivables, net	$	6,955		$	13,130

Other receivables totaled $3,081 and $4,363 as of December 31, 2020 and 2019, respectively, consisting primarily of contract assets and reimbursable costs incurred on behalf of customers. Contract assets consist of products and services provided under specific contracts to customers for which earnings processes have been met prior to shipment of goods or full delivery of completed services. Sales-related allowances for both periods presented are estimated in relation to revenues recognized for sales of Sympazan.

The following table presents the changes in the allowance for bad debt:

	December 31,
	2020			2019
Allowance for doubtful accounts at beginning of year	$	124		$	58
Additions charged to bad debt expense		198			66
Write-downs charged against the allowance		(282	)		—
Allowance for doubtful accounts at end of year	$	40		$	124

The following table presents the changes in sales-related allowances:

	December 31,
	2020			2019
Balance at December 31, 2019	$	203		$	104
Provision related to sales in 2020		731			244
Credits and payments		(518	)		(145	)
Balance at December 31, 2020	$	416		$	203

Concentration of Major Customers

Customers are considered major customers net revenue exceed 10% of total revenue for the period or outstanding receivable balances exceed 10% of total receivables. For the year ended December 31, 2020, two customers exceeded the 10% threshold for revenue which were Indivior, Inc. (“Indivior”) and Sunovion Pharmaceuticals Inc. (“Sunovion”) that represented 57% and 26%, respectively. As of December 31, 2020, four customers exceeded the 10% threshold for outstanding receivables which were Indivior, AmerisourceBergen, Sunovion, and Cardinal represented 53%, 14%, 13%, and 10%, respectively. Revenues provided by Indivior represented approximately 86% for the year ended December 31, 2019 and outstanding accounts receivable due from Indivior was approximately 80%.